All News

When I received my CURE magazine last week, I was fascinated to see a red sticker on the cover indicating it was the lung cancer special edition.

As ‘Big Bang Theory’ star Kate Micucci announced that she is cancer-free and ‘Married at First Sight’ dating coach Mel Schilling announced her cancer diagnosis, here is what’s happening in the oncology space this week.

One expert explained how nurses have “opportunities to get to talk with patients and their loved ones in ways that you don't (get) when you're in the time crunch of an appointment with your oncologist,” and how that can impact end-of-life care.

Treatment with Welireg — now approved by the FDA — helped shrink and stabilize tumors from metastatic renal cell carcinoma with minimal side effects, a patient told CURE®.

Patients with relapsed/refractory large B-cell lymphoma treated with CAR-T cell therapy and bendamustine chemotherapy, experienced lower rates of survival and response as well as shorter times until progression, according to recent study findings.

I spent a week during last Christmas in the oncology ward of a sprawling university hospital in the Midwest.

A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer.

An expert explained what ROS1-positive non-small cell lung cancer is and why it is important to identify mutations like ROS1 through genetic sequencing.

The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.

A recent study found a correlation between perfectionism and fear of cancer recurrence within patients with breast cancer.

The use best use of opioids or NSAIDS may vary based on the type of pain patients with cancer are experiencing, recent research found.

During the holiday season, the most important thing you can do for a patient with cancer is ‘hold space’ for them.

Those caring for loved ones with cancer are “at risk for becoming overwhelmed or becoming so burdened to the point of exhaustion or being sick themselves,” one expert says.

Among patients with relapsed chronic lymphocytic leukemia (CLL) who expressed frequent baseline BTK mutations, responses on the non-covalent BTK inhibitor Jaypirca remained high, according to data presented at the 2023 ASH Annual Meeting.

An expert spoke with CURE® about telehealth when it comes to ostomies within patients with bladder cancer, and overall within patients and survivors.

An expert discusses how the use of robotic surgery improves the lives of patients with cancer, and looks forward to advancements that may come in 2024 and beyond.

A nurse practitioner talks about personalized therapy and the role that genomic testing plays for patients with breast cancer.

I was asked if I celebrate my cancer journey dates... here is what I said.

Breast cancer treatment can disrupt patients’ quality and quantity of sleep, leaving them fatigued and restless during the day.

A treatment combination of Sarclisa, Kyprolis, Revlimid and dexamethasone demonstrated a complete response in patients who were newly diagnosed with multiple myeloma.

An expert discussed the importance of knowing the questions to ask a patient’s care team to navigate one’s journey, including treatment and next steps.

After being diagnosed with stage 3 liposarcoma, my life’s choices came sharply into focus.

New tools help manage ESR1 mutations in metastatic breast cancer.

As a caregiver, it can be challenging to navigate the holidays.

Dr. Stephanie Berg of the Dana-Farber Cancer Institute and Harvard Medical School discussed the recent EMARK trial which resulted in the FDA’s approval of Xtandi for non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis.

One expert explains how patients’ wishes for their end-of-life care can change with time, making those conversations with caregivers “not a one-time, sit-down discussion.”

Patients with chemotherapy-naïve, HER2-low hormone receptor-positive metastatic breast cancer experienced antitumor activity via combination therapy with Arimidex or Faslodex plus Enhertu, according to data from the phase 1b DESTINY-Breast08 trial.

Oct. 8, 2019 was the last day of chemotherapy for my girl.